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ABSTRACT
Introduction Programme for Improving Mental Health 
Care (PRIME) designed a comprehensive mental healthcare 
plan (MHCP) for Sehore district, Madhya Pradesh, India. 
The objective of this paper is to describe the findings of the 
district-level impact evaluation of the MHCP.
Methods Repeat community-based CS were conducted 
to measure change in population-level contact coverage 
for depression and alcohol use disorders (AUD), repeat 
FDS were conducted to assess change in detection and 
initiation of treatment for depression and AUD, and the 
effect of treatment on patient outcomes was assessed 
using disorder-specific prospective cohort studies.
Results PRIME MHCP did not have any impact on contact 
coverage/treatment seeking for depression (14.8% at 
the baseline and 10.5% at the follow-up) and AUD (7.7% 
at the baseline and 7.3% at the follow-up) and had a 
small impact on detection and initiation of treatment for 
depression and AUD (9.7% for depression and 17.8% 
for AUD compared with 0% for both at the baseline) 
in the health facilities. Patients with depression who 
received care as part of the MHCP had higher rates of 
response (52.2% in the treatment group vs 26.9% in the 
comparison/usual care group), early remission (70.2% in 
the treatment group vs 44.8% in the comparison/usual 
care group) and recovery (56.1% in the treatment group vs 
28.5% in the comparison/usual care group), but there was 
no impact of treatment on their functioning.
Conclusions While dedicated human resources (eg, Case 
Managers) and dedicated space for mental health clinics (eg, 
Mann-Kaksha) strengthen the ‘formal’ healthcare platform, 
without substantial additional investments in staff, such as 
Community Health Workers/Accredited Social Health Activists 
to improve community level processes and provision of 
community-based continuing care to patients, we are unlikely to 
see major changes in coverage or clinical outcomes.
InTRoduCTIon
In India, the weighted prevalence of any 
mental disorder is 10.6% (point prevalence) 
and 13.7% (lifetime prevalence) as per the 
findings of the National Mental Health 
Survey.1 Mental disorders account for 31 
million Disability Adjusted Life Years, which 
is 13% of the total non-communicable disease 
burden in India.2 Unfortunately, the access to 
mental healthcare in India is very poor due 
to multiple demand and supply side barriers 
Key questions
What is already known?
 ► World Health Organization’s mhGAP (Mental Health 
Gap Action Programme) guidelines have synthesized 
evidence-based interventions (e.g. psychotropic 
drugs, psycho-social interventions) to treat mental 
disorders. The key knowledge gap is about how to 
integrate these evidence-based interventions in pri-
mary care in low resource settings.
 ► For Improving Mental health carE (PRIME) designed 
a comprehensive district level Mental Health Care 
Plan (MHCP) to address this knowledge gap.
What are the new findings?
 ► PRIME MHCP did not have any impact on contact 
coverage for depression and AUD at the community 
level and a small impact on detection and initiation 
of treatment for depression and AUD in the health 
facilities. At the individual patient level, there was 
moderate impact of MHCP interventions.
What do the new findings imply?
 ► Establishing a collaborative model of care remains 
a very challenging task, especially in resource poor 
settings. However, facilitation by an implementation 
support team can play an important role in strength-
ening mental health services.
 ► Psychosocial therapies cannot be effectively deliv-
ered without engaging existing or new communi-
ty-based resources.
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and this has led to a huge treatment gap for mental disor-
ders. The treatment gap for common mental disorders is 
85% and for severe mental disorders it is 73.6%.1
Three key policy initiatives viz., the National Mental 
Health Policy launched in 2014, the new National Health 
Policy3 and most importantly, the Mental Health Care 
Act,4 provide a unique opportunity to bridge this treat-
ment gap in India.4 However, there are very few evidence-
based implementation models in India which provide a 
plan to integrate mental healthcare delivery in existing 
primary healthcare system which can ultimately improve 
access to care. In this context, the work of the Programme 
for Improving Mental Health Care (PRIME) is a potential 
model for strengthening mental health services in India. 
PRIME began in 2011 as an implementation research 
effort to understand the best strategies for integrating 
evidence-based mental health interventions into the 
primary healthcare system, and includes five countries: 
Ethiopia, India, Nepal, South Africa and Uganda.5
In India, PRIME was implemented in the state of Madhya 
Pradesh. As part of the inception phase of PRIME, a draft 
district mental healthcare plan (MHCP) was developed 
(described below).6 A comprehensive, cross-country eval-
uation protocol was designed to assess the impact of the 
PRIME MHCP.7 In this paper, we describe the findings of 
the community, facility and individual level impact of the 
implementation of PRIME MHCP.
MeTHodS
Setting
Sehore district in Madhya Pradesh was the implementa-
tion site for PRIME in India. It has a population of 1.3 
million which is predominantly rural (81%) and the 
district covers an area of 6578 km2. Situational analysis 
identified a range of major health system challenges in 
developing and implementing MHCP in Sehore district. 
Poor governance, lack of sustainable mental health 
financing measures, severe shortages of skilled mental 
health professionals in the public health system, very few 
capacity building initiatives for general health profes-
sionals and non-specialists health workers, non-availa-
bility of essential psychotropic drugs, under-developed 
mental health information systems and low mental 
health literacy and stigma against people with mental 
disorders resulted in non-integration of mental health in 
primary care in Sehore district.8 During the first 2 years 
of the programme, a comprehensive MHCP for Sehore 
district was designed in partnership with the Department 
of Health Services, Government of Madhya Pradesh 
and other key stakeholders. This was followed by a pilot 
implementation in one community health centre (CHC) 
and refinement of the draft MHCP.
Programme for Improving Mental Health Care mental 
healthcare plan
PRIME MHCP was implemented in three CHCs in Sehore 
district for a period of 25 months from 1 August 2014 
till 31 August 2016. Initially, the plan was to implement 
MHCP in the entire Sehore district. However, during the 
inception phase, we realised that there are several health 
system and contextual challenges to programme imple-
mentation and that strong facilitation was necessary in 
order to instal, optimise and improve service delivery 
processes. Based on the human resource we had in the 
PRIME programme (one programme coordinator and 
six Case Managers), it was feasible to implement the 
programme in one subunit/block of the district which 
had three CHCs/Sub-District Hospitals. These CHCs 
provide services to 239 villages covering a population of 
268 833.
PRIME MHCP consisted of service delivery and 
enabling packages. The enabling packages comprised 
cross-cutting interventions to ensure the smooth imple-
mentation of core mental health service delivery pack-
ages. There were three enabling packages: programme 
management, capacity building and community mobil-
isation. Programme management activities related to 
governance, human resource management and drug 
procurement and supply chain management started in 
March 2014. Training of Medical Officers, Front Line 
Workers and Case Managers was conducted from March 
to July 2014. A Health Management Information System 
was established in last week of July 2014 and regular 
process data were collected from 1 August 2014 until the 
end of the implementation phase (31 August 2016).
The four service delivery packages were awareness 
creation, identification, treatment and recovery for 
three priority mental disorders: depression (including 
maternal depression), psychosis and alcohol use disor-
ders (AUD). Mental health services were delivered on 
healthcare platform and community platform.
Mental health Case Managers employed by PRIME 
played a very important role in implementation of 
MHCP. There was a total of six Case Managers, two 
(one male and one female) Case Managers in each of 
the CHC. A room was allocated in each CHC for provi-
sion of mental health services. This room was named as 
‘Mann-Kaksha’ (translated as ‘Mental Health Corner’ in 
English) and was managed by the Case Managers. Case 
Managers contacted patients attending outpatient clinics 
and if their presenting complaints were similar to those 
mentioned in the master chart of the mental health 
Gap Action Programme (mhGAP) intervention guide, 
they screened the patients using Patient Health Ques-
tionnaire-9 item (PHQ-9) (for depression) and Alcohol 
Use Disorder Identification Test (AUDIT) (for AUD). 
Case Managers shared PHQ-9/AUDIT scores with the 
Medical Officer who made the diagnosis and took the 
decision to prescribe anti-depressants/other medica-
tions depending on the severity. Patients who received 
confirmed diagnosis of depression/AUD by the Medical 
Officer were offered counselling treatment in the form 
of Healthy Activity Programme (HAP, for depression) 
or Counselling for Alcohol Problems (CAP, for AUD). 
If they agreed, they were enrolled in the programme. 
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Generally, patients with PHQ-9 >14 received both anti-de-
pressants and counselling while those with PHQ-9 ≤14 
received only counselling. HAP is a manualised psycho-
logical treatment based on behavioural activation and it 
includes (1) psycho-education, (2) behavioural assess-
ment, (3) activity monitoring, (4) activity structuring 
and scheduling, (5) activation of social networks and 
(6) problem solving.9 CAP is a manualised psychological 
treatment based on motivational interviewing.10 Women 
attending antenatal/postnatal clinics were also screened 
by Case Managers and if found positive for depression, 
they were offered HAP. The District Mental Health 
Programme Psychiatrist visited each of the CHCs once 
a month to provide consultation for severe cases, espe-
cially those with psychosis. Patients with psychosis were 
primarily identified by Case Managers in the community 
(see below). For these patients (and their caregivers), 
Case Managers provided psychoeducation and facilitated 
consultation with the Psychiatrist. Case Managers main-
tained regular follow-up with enrolled patients.
In addition to these services which were offered on 
healthcare platform, Case Managers visited villages which 
were under their respective CHCs to provide services on 
the community platform. During their visit to a village, 
Case Managers would meet community health workers 
(CHWs) in that village (eg, Accredited Social Health 
Activist, ASHA) and based on their inputs, contacted indi-
viduals to assess them for priority mental disorders using 
the master chart of the mhGAP intervention guide. Case 
Managers provided Mental Health First Aid (MHFA)11 to 
these individuals and if they felt the need for further eval-
uation and management, a referral slip to visit the CHC 
was provided.
overview of the study design
The overall aim of PRIME MHCP was to improve demand 
for mental health services at the population/community 
level, reduce the ‘missed opportunity’ at the health facility 
level by improving detection of depression and alcohol 
use disorder (AUD) and provide evidence-based services 
to individuals with priority mental disorders (depression, 
AUD and psychosis).
Hence, in the evaluation plan to assess the impact of 
district MHCP, outcomes at three levels were considered, 
namely population, health facility and individual/patient 
level. Our approach was guided by Tanahashi framework 
(used to evaluate coverage of services in a public health 
programme), a Theory of Change map and the multidis-
ciplinary methods embedded within this theory.7
The following study designs were employed to evaluate 
the above mentioned MHCP outcomes:
a. Repeat community-based cross-sectional surveys (CS) 
to measure change in population-level contact cover-
age for depression and AUD.
b. Repeat facility-based detection surveys (FDS) to assess 
change in detection and initiation of treatment for de-
pression and AUD.
c. Disorder-specific prospective cohort studies to assess 
the effect of treatment on patient outcomes (effective 
coverage).
In addition to this, a multilevel case study was also 
undertaken to evaluate the process of implementation. 
A summary of the process data relevant to study designs 
included in this paper are presented in the results 
sections.
The timeline of baseline and follow-up CS and FDS, 
cohort study and implementation of PRIME MHCP is 
depicted in figure 1.
Patient and public involvement
The development of the MHCP and the evaluation frame-
work (including the research questions and outcome 
measures) was based on the Theory of Change work-
shops and qualitative data obtained during the inception 
phase. Key stakeholders such as service providers in the 
public health system, community members and patients 
were involved during this work in the inception phase.6 
Community Advisory Board was established to provide 
feedback and inputs during the implementation phase, 
however, patients were not involved in the recruitment 
and conduct of the study. At the end of the programme, 
there is a plan to disseminate results to the members of 
the Community Advisory Board, patients and general 
community members in Sehore district.
The section below separately describes data collection 
methods, outcomes assessment and statistical analysis for 
community survey, facility detection survey and patient 
cohorts, respectively.
Community survey
The baseline community survey was completed in 
2013–2014 before the implementation of MHCP. The 
baseline prevalence and contact coverage for depres-
sion12 and AUD13 are reported in previous publications. 
The follow-up survey was conducted from October to 
December 2016, 26 months after the initiation of PRIME 
MHCP implementation.
Sample selection
There are 1031 villages and eight towns in Sehore 
district. The total population of Sehore district is 1 311 
332 (rural: 1 062 870, urban: 248 462). After the comple-
tion of baseline community survey, the decision was 
taken to implement PRIME MHCP in only three CHCs 
as mentioned above. As a result, the sample for follow-up 
survey was selected from only those villages which were 
under PRIME CHCs. Of the total 239 villages which are 
officially covered by these three CHCs, effectively people 
from only 188 villages access health services from these 
CHCs and people from the rest of the 51 villages access 
services from Sehore town or Bhopal (capital of Madhya 
Pradesh) due to geographical proximity. Thus, the 
sample for follow-up survey was restricted to 188 villages 
(total population of 213 187) as this was the effective 
implementation area for community platform activities. 
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Figure 1 Programme for Improving Mental Health Care India mental healthcare plan timelines. FDS, facility-based detection 
surveys.
From the baseline community survey, there were 1305 
participants from 188 villages. In the follow-up commu-
nity survey, the sample size was set to detect a change 
in contact coverage/treatment seeking from 7.7% (base-
line) to 25% for AUD, which we considered was a mean-
ingful increase from a population health perspective. As 
the prevalence and contact coverage/treatment seeking 
for AUD was almost half that of depression, the estimates 
were done for AUD so that we were assured sufficient 
power for the depression analyses. The sampling frame 
for follow-up survey comprised adults (18 years or old) 
selected from voter lists in 188 villages from the imple-
mentation area. The voter lists were obtained from 
the website of the Election Commission of India. The 
sample was selected from each of the voter lists. The 
number of individuals sampled per voter list was esti-
mated according to the proportional contribution of the 
voter list to the total population. The first individual in 
the sample was randomly selected and then every nth 
individual was selected based on the sampling interval. 
Inclusion criteria for participation were fluency in 
spoken Hindi, residency in the selected household, time 
and ability to complete the full interview, willingness to 
provide informed consent, and absence of any cognitive 
impairment that was severe enough to interfere with the 
informed consent procedure or survey.
Data collection
The structured-interview schedule used for the follow-up 
survey was the same as the one used for the baseline 
survey (with some additional items related to travel time 
and costs to seek mental health services). Depression 
and AUD were measured using the PHQ-9 and AUDIT, 
respectively, which are validated and widely used in 
India.14–16 Participants who scored 10 or more on PHQ-9 
were taken as probable cases of depression, partici-
pants who scored eight or more on AUDIT were taken 
to indicate probable cases of AUD. Probable cases were 
then asked questions related to seeking help for depres-
sion-related and AUD-related problems from specialist, 
generalist or non-formal providers in the past 12 months. 
Details about the treatment received, medications and 
costs of care (incurred by the individual) were elicited. 
Participants were then asked questions on suicidal idea-
tion, adapted from the Mini-International Neuropsychi-
atric Interview, a semi-structured interview for the assess-
ment of mental disorders. Sociodemographic factors 
assessed included possession of below poverty line card 
and employment with Mahatma Gandhi National Rural 
Employment Guarantee Act, both indicators of socioec-
onomic deprivation. The structured interview for the CS 
(as well as for the FDS and the cohort study) was adminis-
tered using tablet computers linked to an online applica-
tion programme (Mobenzi; www. mobenzi. com).
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Outcomes
Our primary outcome was to measure change in contact 
coverage 26 months after the PRIME implementation 
began in August 2014, defined as the difference in 
the proportion of individuals with depression or AUD 
(PHQ-9 score ≥10 and AUDIT score ≥8, respectively) 
who sought treatment for their symptoms after the base-
line survey.
Statistical analysis
The sociodemographic characteristics of the baseline 
survey population and the follow-up survey population 
were treated as categorical variables and compared 
with the χ2 test. Second, for both PHQ9-positive and 
AUDIT-positive participants, the number, proportion 
and 95% CI were reported for detection and for initia-
tion of adequate evidence-based treatment. All analyses 
for the CS (as well as for the FDS and the cohort study) 
were conducted in Stata V.14.117 and design-adjusted for 
the sampling design.
Facility detection survey
The baseline FDS was conducted prior to implementa-
tion of the MHCP and the follow-up survey was completed 
from September to October 2016, 30 months after the 
first training of medical officers and 3 months after the 
last refresher training of medical officers.
Sample selection
Systematic random sampling was employed to collect a 
sample of patients exiting their clinical consultations in 
the three CHCs in the PRIME implementation area. The 
inclusion criteria for participation were the same as in 
the community survey, except that patients presenting 
with acute medical conditions were also excluded. Our 
sample size calculation was based on the assumption that 
the detection of depression and AUD would increase 
from 1% to 33%. With 90% power and level of signifi-
cance of 5%, we needed a sample size of 33 patients with 
AUD. In order to obtain the required sample size of 33, 
we needed to approach 726 individuals. This was based 
on the assumption of 5% prevalence of AUD in primary 
care and 10% rejection rate for interviews. The sample 
size of 726 provided us with 95% power to detect change 
in detection of depression from 1% to 33% with the 
assumption of 10% prevalence of depression in primary 
care and 10% rejection rate.
Data collection
The structured interview consisted of sections pertaining 
to: sociodemographic characteristics; recent use of 
alcohol and tobacco; screening for AUD; screening for 
depression; details about the clinical consultation.
Outcomes
The outcome of interest was the estimation of the change 
in proportions receiving mental disorder-specific clinical 
services over time, including (1) diagnosis of depres-
sion or AUD by the primary healthcare worker and (2) 
initiation of minimal-adequate treatment plan by the 
primary healthcare worker. Ascertainment of the mini-
mal-adequate treatment plan was based on the following 
criteria: (1) relevant advice (psychoeducation/psycho-
logical intervention) for reducing symptom severity; (2) 
an appropriate specialist referral; (3) an appropriate 
medication regimen; or (4) a combination of (1), (2) or 
(3). These outcomes were assessed by collecting informa-
tion from the patient through a postconsultation inter-
view that asked the patient whether they received a diag-
nosis, treatment plan or referral.
Statistical analysis
The sociodemographic characteristics of the baseline 
survey population and the follow-up survey population 
were treated as categorical variables and compared with 
the χ2 test. Proportion of patients with depression and 
AUD receiving diagnosis and initiation of treatment was 
estimated and 95% CIs were compared. All analyses were 
conducted in Stata V.14.1.17
Cohort study
Sample selection
Recruitment into the depression, AUD and psychosis 
cohorts was initiated 3 months after the start of the 
MHCP implementation in Sehore district. During this 
time, initial training of staff and setting up of supervision 
and leadership processes were completed. This allowed 
for the services to run for several weeks before recruit-
ment started. Participants were recruited from outpa-
tient clinics in the three CHCs implementing the MHCP. 
Patients attending outpatient clinic were screened with 
the PHQ-9 and AUDIT by Case Managers, and were then 
assessed and diagnosed by medical officers. Patients who 
received either a diagnosis of depression or AUD and 
referred for treatment were recruited in the respective 
cohorts. The depression treatment cohort was further 
divided into two cohorts: general depression (non-per-
inatal population) and maternal depression (perinatal 
population). Women were considered perinatal if they 
were either pregnant or had a child younger than 1 year 
old. Treatment for severe mental disorders had priority 
over common disorders, so if patients were diagnosed 
with psychosis, patients were recruited into the psychosis 
cohort, regardless of their screening scores on the PHQ-9 
and AUDIT. Not all patients attending outpatient clinic 
were screened by Case Managers due to time constraints. 
These patients, however, did consult the medical officer 
for their health complaints. Research team members 
then randomly screened these individuals in outpatient 
clinics after they completed consultation with the medical 
officer. Individuals who were not diagnosed by medical 
officers, but screened positive on PHQ-9 or AUDIT (by 
a research team member) were recruited as comparison 
groups (as they had not been diagnosed or referred 
to treatment). Participants in the comparison group 
received usual care for their general health complaints 
from the medical officer. They did not receive any mental 
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health interventions. There were no perinatal women in 
the depression comparison group. The target sample size 
was set at 200 for depression and AUD cohorts, and 150 
for the psychosis cohort. The details of the data collection 
and sample size calculation are provided elsewhere.18
Data collection
All participants were assessed three times: the baseline 
assessment was initiated at the clinic following enrolment 
into the cohorts (including the PHQ-9 and AUDIT), and 
finalised in the participants’ home (including demo-
graphic variables and the WHO Disability Assessment 
Schedule (WHODAS)). The time elapsed between the 
enrolment of patients and the completion of the baseline 
interview could not exceed 7 days, and was completed on 
average 3 days after enrolment. The first follow-up was 
conducted 3 months after recruitment (±2 weeks) for the 
depression, maternal depression and AUD cohorts, and 
6 months (±2 weeks) after recruitment for the psychosis 
cohort. The second and final follow-up was conducted 12 
months after recruitment (±4 weeks) for all four cohorts. 
Follow-up assessments were conducted in a private space 
at the participants’ home. All assessments comprised a 
range of measures, including socio-demographic and 
economic measures, clinical severity measures, as well as 
healthcare expenditure measures, stigma and discrimina-
tion measures.18
Participants who could not be reached within the 
window period after at least three contact attempts 
were considered suspended until the next assessment, 
when an attempt to contact them was made again. The 
reason for suspending participants from follow-up was 
recorded. Participants who actively refused to be assessed 
at follow-up were withdrawn from the study. Suspensions 
from assessments or withdrawals from the study did not, 
however, affect the care participants in the treatment 
cohorts were receiving as part of the MHCP. Participants 
who, on the other hand, refused or discontinued treat-
ment remained in the cohort and were still followed up 
for their assessments.
Outcomes
Primary outcomes for all cohorts was change in symptom 
severity, measured using the PHQ-9 (depression and 
maternal depression cohorts) and the AUDIT (AUD 
cohort). There was no symptom severity outcome for the 
psychosis cohort. Secondary outcomes for the depression 
cohort was response at each follow-up assessment, defined 
as a minimum 50% decrease in PHQ-9 score compared 
with baseline, as well as early remission (PHQ-9 <10 at 3 
months), late remission (PHQ-9 <10 at 12 months but not 
at 3 months) and recovery (PHQ-9 <10 at both 3 and 12 
months). Late remission was also a secondary outcome for 
the AUD cohort, defined as AUDIT <8 at 12 months. In 
addition to this, functioning at each follow-up, measured 
using the 12-item WHO Disability Assessment Schedule 
(WHODAS V.2.0) was included as a secondary outcome. 
A software malfunction prevented the measurement of 
the AUDIT among the AUD cohort at 3 months after 
recruitment. In the case of the psychosis cohort only 
functioning was assessed using WHODAS V.2.0.
Statistical analysis
None of the continuous outcome measures (eg, 
WHODAS, PHQ-9, AUDIT) were normally distributed, 
and so count regression models were used to assess these 
outcomes.19 20 More specifically, for the depression and 
AUD cohorts, mixed-effect negative binomial regression 
was used to assess difference-in-differences of outcome 
means at each time point in comparison to the baseline. 
Mixed-effect logistic regression was used to assess change 
in binary outcomes (response, early remission, late 
remission and recovery). Analysis was as per intention to 
treat and baseline imbalances in sociodemographic and 
clinical measures between the treatment and compar-
ison groups in the depression and AUD cohorts were 
adjusted in the models. Non-parametric paired tests were 
conducted to assess change in PHQ-9 and/or WHODAS 
scores in the maternal depression and psychosis cohorts, 
due to the small sample sizes.
To assess equity in change in PHQ-9 (depression 
cohort) and AUDIT (AUD cohort) from baseline to 12 
months across demographic groups, mixed effects nega-
tive binomial regression was performed again, this time 
including each demographic variable as an interaction 
term in the model; this was followed by Wald chi square 
tests. Equity in change in PHQ-9 scores (maternal depres-
sion cohort) and WHODAS scores (psychosis cohort) was 
assessed using non-parametric tests (Mann-Whitney U or 
Kruskal-Wallis tests).
ReSulTS
Community survey
Characteristics of the participants
In the baseline community survey, 3233 of 5170 randomly 
selected individuals were located (62.5%), and interviews 
were completed with 3220 participants. In the current 
analysis, we use data of 1305 participants who belonged 
to the PRIME implementation area (the baseline sample 
population for this paper). In the follow-up community 
survey, 2970 of 3898 randomly selected individuals were 
located (76.2%) and interviews were completed with 
2867 participants (98.5%) which constitutes the follow-up 
survey population. Higher proportion of people in the 
baseline sample were younger, males, less educated and 
unemployed (table 1).
Process data (community processes)
PRIME was implemented in three CHCs which provide 
services to 239 villages and cover a population of 268 833. 
PRIME Case Managers were able to visit and undertake 
community activities in only 136 villages (57.6% of total 
villages under three CHCs) which had a total population 
of 164 440 (approximately 98 664 adults assuming 60% 
of the total population is adult). They visited these 136 
villages at least once during the implementation period. 
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Table 2 Impact of Programme for Improving Mental Health Care mental healthcare plan on community and facility level 
outcomes
Depression Alcohol use disorders
Baseline contact 
coverage (% with 95% 
CI)
Follow-up contact 
coverage (% with 95% 
CI)
Baseline contact 
coverage (% with 95% 
CI)
Follow-up contact 
coverage (% with 95% 
CI)
Community Survey 14.8 (11.1 to 19.4) 10.5 (7.6 to 14.3) 7.7 (2.8 to 19.5) 7.3 (3.1 to 16.2)
 
Baseline detection 
coverage (% with 95% 
CI)
Follow-up detection 
coverage (% with 95% 
CI)
Baseline detection 
coverage (% with 95% 
CI)
Follow-up detection 
coverage (% with 95% 
CI)
Facility Detection 
Survey
0.0 9.7 (5.5 to 14.0) 0.0 17.8 (6.6 to 28.9)
They screened 5540 individuals (5.6% of the total adult 
population) and referred 1428 (25.9%) to the facilities 
for further management. Among those who received the 
referral slips, 274 (19.2%) individuals came to the CHC 
to seek services and 189 (69%) of them were enrolled 
in the PRIME programme and received PRIME interven-
tions.
Community level outcomes
The contact coverage in the baseline community survey 
was 14.8% (95% CI 11.1% to 19.4%) for depression and 
7.7% (95% CI 2.8% to 19.5%) for AUD. There was no 
evidence of change in contact coverage for depression 
and AUD after implementation of PRIME MHCP. In the 
follow-up community survey, the contact coverage for 
depression was 10.5% (95% CI 7.6% to 14.3%) and for 
AUD it was 7.3% (95% CI 3.1% to 16.2%).
Facility detection survey
Characteristics of the participants
In the baseline FDS, 760 randomly selected patients 
attending CHC outpatient clinic were contacted and 
interviews were completed with 760 (100%) partici-
pants (the baseline sample population). In the follow-up 
FDS, 920 randomly selected patients attending CHC 
outpatient clinic were contacted and interviews were 
completed with 817 (88.8%) participants (the follow-up 
sample population). Higher proportion of people in 
the baseline sample were younger, illiterate, didn’t have 
partner, unemployed and belonged to Muslim (or other) 
religion (table 1).
Process data (facility processes)
During the implementation period, a total of 131 884 
outpatient clinic visits were recorded. Case Managers 
were able to screen 15 130 patients. Out of those 
screened, 1109 (7.3%) were enrolled to receive treat-
ment for depression and 617 (4.1%) were enrolled to 
receive treatment for AUD.
Facility level outcomes
In the baseline FDS, none of the individuals attending 
outpatient clinic and who had depression or AUD were 
diagnosed with these conditions and therefore none of 
them received treatment. In the follow-up survey, 9.7% 
(95% CI 5.5% to 14.0%) of all the individuals who had 
depression and who were attending the outpatient 
department (OPD), were diagnosed with depression and 
were initiated on treatment. 19 participants were diag-
nosed with depression by medical officers, out of these 
18 (94.7%) were true positive while 1 (5.3%) was false 
positive. 17.8% (95% CI 6.6% to 28.9%) of all the indi-
viduals who had AUD and who were attending the OPD, 
were diagnosed with AUD and were initiated on treat-
ment (table 2).
Cohort study
Depression
Characteristics of the participants
A total of 240 participants were recruited in the depres-
sion treatment cohort at baseline, and 149 participants in 
the comparison group. Two participants in the treatment 
cohort scored below 10 on the PHQ-9 at baseline, so 
they were excluded from the analysis. The demographic 
characteristics of the depression cohort’s final sample 
are reported in table 1. The proportion of females 
and those who reported not having a partner (single/
divorced/widowed) was much greater in the depression 
treatment group compared with the comparison group. 
The patients in the treatment group were also much 
younger and unemployed (table 1). To adjust for these 
differences, all subsequent regression models controlled 
for gender, age, marital status and employment status. 
Baseline WHODAS and PHQ-9 scores were also different 
between the two groups, and so these were also included 
in the models.
The follow-up rates at 3 months were 90.6% and 85.3% 
for the comparison and treatment groups, respectively, 
and 87.9% and 80.3% at 12 months (figure 2).
A further 41 perinatal women were recruited into 
the depression cohort and analysed separately. All were 
married and nearly all were between the ages of 18 and 
29 (n=38, 92.7%), Muslim (n=38, 92.7%), unemployed 
(n=39, 95.1%) but food secure (n=40, 97.6%). Over half 
reported having achieved primary education or above 
(n=27, 65.8%).
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Figure 2 Flow diagram of recruitment and follow-up process for the depression cohort. PHQ-9, Patient Health 
Questionnaire-9 item.
A total of 38 (92.7%) and 33 (80.5%) participants were 
followed up at 3 months and 12 months after recruit-
ment, respectively.
Process data (depression and maternal depression cohort 
participants)
Of the 238 treatment participants, HAP was offered to 
all, and the first session of HAP was completed by 221 
(92.9%) of participants. Only 34 participants (14.3%) 
completed four sessions of HAP. Treatment closure was 
done for 18 (7.6%) participants. Anti-depressants were 
prescribed to 177 participants (74%).
In case of perinatal women, first session of HAP was 
delivered to 40 participants (98%). However, it was very 
difficult to have follow-up sessions with them and only 
three participants (7.3%) received a second session of 
HAP.
Patient level outcomes
There was a significant difference in symptom severity 
reduction at 3 months between the intervention and 
comparison group of the depression cohort (table 3): 
participants in the intervention group had a mean PHQ-9 
score of 14.5 (SD=3.22) at baseline, which decreased by 
6.02 (95% CI −7.00 to 5.05) points at midline, whereas 
the participants in the comparison group saw their scores 
reduce by 3.18 points (95% CI −4.04 to 2.31), from a 
mean score of 13.4 (SD=2.63) at baseline. The difference 
in reduction in mean PHQ-9 score between the interven-
tion and comparison group at midline (β=−2.85; 95% 
CI −3.88 to 1.81) and endline (β=−2.57; 95% CI −3.58 
to −1.55) was clinically significant. This is also supported 
by difference in response and remission rates for depres-
sion.
 o
n
 4 June 2019 by guest. Protected by copyright.
http://gh.bmj.com/
BM
J G
lob Health: first published as 10.1136/bmjgh-2018-001344 on 19 May 2019. Downloaded from 
10 Shidhaye R, et al. BMJ Global Health 2019;4:e001344. doi:10.1136/bmjgh-2018-001344
BMJ Global Health
Ta
b
le
 3
 
Im
p
ac
t 
of
 P
ro
gr
am
m
e 
fo
r 
Im
p
ro
vi
ng
 M
en
ta
l H
ea
lth
 C
ar
e 
m
en
ta
l h
ea
lth
ca
re
 p
la
n 
on
 in
d
iv
id
ua
l l
ev
el
 o
ut
co
m
es
 in
 t
he
 d
ep
re
ss
io
n 
an
d
 A
U
D
 c
oh
or
t
C
o
m
p
ar
is
o
n 
g
ro
up
Tr
ea
tm
en
t 
g
ro
up
U
na
d
ju
st
ed
 β
 o
r 
R
R
 (9
5%
 C
I)
A
d
ju
st
ed
 β
 o
r 
R
R
 (9
5%
 C
I)
N
M
ea
n 
(S
D
) o
r 
N
 (%
)
A
d
ju
st
ed
 m
ea
n 
ch
an
g
e 
(9
5%
 
C
I) 
fr
o
m
 B
L
N
M
ea
n 
(S
D
) o
r 
N
 (%
)
A
d
ju
st
ed
 m
ea
n 
ch
an
g
e 
(9
5%
 
C
I) 
fr
o
m
 B
L
D
ep
re
ss
io
n 
co
ho
rt
 
 P
H
Q
-9
 s
co
re
 
 B
as
el
in
e
14
9
13
.4
 (2
.6
3)
–
23
8
14
.5
 (3
.2
2)
–
 
 M
id
lin
e
13
4
9.
6 
(4
.1
8)
−
3.
18
 (−
4.
04
 t
o 
−
2.
31
)
20
1
7.
5 
(3
.9
2)
−
6.
02
 (−
7.
00
 t
o 
−
5.
05
)
−
3.
22
 (−
4.
35
2 
to
 −
2.
09
)
−
2.
85
 (−
3.
88
 t
o 
−
1.
81
)*
**
 
 E
nd
lin
e
13
1
9.
0 
(3
.9
8)
−
3.
69
 (−
4.
59
 t
o 
−
2.
79
)
19
1
7.
3 
(4
.1
5)
−
6.
26
 (−
7.
25
 t
o 
−
5.
26
)
−
2.
88
 (−
4.
00
 t
o 
−
1.
76
)
−
2.
57
 (−
3.
58
 t
o 
−
1.
55
)*
**
 
 W
H
O
D
A
S
 s
co
re
 
 B
as
el
in
e
14
4
30
.7
 (1
3.
71
)
–
21
7
26
.4
 (1
5.
14
)
 
 M
id
lin
e
13
5
26
.8
 (1
3.
59
)
−
3.
52
 (−
6.
08
 t
o 
−
0.
97
)
20
3
21
.2
 (1
1.
22
)
−
4.
07
 (−
5.
89
 t
o 
−
2.
25
)
−
0.
69
 (−
4.
44
 t
o 
3.
06
)
−
0.
55
 (−
3.
50
 t
o 
2.
41
)
 
 E
nd
lin
e
13
0
26
.9
 (1
2.
87
)
−
3.
61
 (−
6.
18
 t
o 
−
1.
04
)
19
1
22
.8
 (1
1.
93
)
−
2.
82
 (−
4.
61
 t
o 
−
1.
04
)
0.
90
 (−
2.
92
 t
o 
4.
73
)
0.
79
 (−
2.
22
 t
o 
3.
80
)
 
 R
es
p
on
se
 (P
H
Q
-9
)
 
 M
id
lin
e
13
4
36
 (2
6.
9)
–
20
1
10
5 
(5
2.
2)
–
1.
94
 (1
.4
3 
to
 2
.6
5)
1.
68
 (1
.2
2 
to
 2
.3
0)
**
 
 E
nd
lin
e
13
1
40
 (3
0.
5)
–
19
1
10
9 
(5
7.
1)
–
1.
87
 (1
.4
0 
to
 2
.4
9)
1.
56
 (1
.1
6 
to
 2
.1
0)
**
 
 E
ar
ly
 r
em
is
si
on
 (P
H
Q
-9
)
13
4
60
 (4
4.
8)
–
20
1
14
1 
(7
0.
2)
–
1.
57
 (1
.2
7 
to
 1
.9
3)
1.
50
 (1
.2
1 
to
 1
.8
7)
**
*
 
 La
te
 r
em
is
si
on
 (P
H
Q
-9
)
73
31
 (4
2.
5)
–
57
29
 (5
0.
9)
–
1.
20
 (0
.8
3 
to
 1
.7
3)
1.
24
 (0
.8
4 
to
 1
.8
4)
 
 R
ec
ov
er
y 
(P
H
Q
-9
)
13
0
37
 (2
8.
5)
–
18
9
10
6 
(5
6.
1)
–
1.
97
 (1
.4
6 
to
 2
.6
6)
1.
82
 (1
.3
3 
to
 2
.4
8)
**
*
A
U
D
 C
oh
or
t
 
 A
U
D
IT
 S
co
re
 
 B
as
el
in
e
14
7
14
.3
 (4
.8
8)
–
21
7
18
.4
 (7
.7
6)
–
–
–
 
 E
nd
lin
e
10
4
10
.4
 (5
.4
4)
−
3.
32
 (−
4.
47
 t
o 
−
2.
17
)
13
7
11
.3
 (7
.4
8)
−
6.
03
 (−
7.
21
 t
o 
−
4.
85
)
−
3.
23
 (−
5.
14
 t
o 
−
1.
33
)
−
2.
71
 (−
4.
29
 t
o 
−
1.
13
)*
*
 
 W
H
D
O
A
S
 s
co
re
 
 B
as
el
in
e
13
5
22
.4
 (1
1.
73
)
20
4
19
.4
 (1
2.
80
)
 
 M
id
lin
e
12
8
21
.7
 (1
0.
23
)
−
0.
54
 (−
2.
94
 t
o 
1.
86
)
19
0
18
.2
 (1
0.
64
)
−
0.
66
 (−
2.
20
 t
o 
0.
89
)
−
0.
33
 (−
3.
64
 t
o 
2.
98
)
0.
12
 (−
2.
97
 t
o 
2.
74
)
 
 E
nd
lin
e
11
8
22
.2
 (1
2.
41
)
−
0.
58
 (−
3.
05
 t
o 
1.
88
)
17
4
19
.4
 (1
0.
21
)
0.
56
 (−
1.
08
 t
o 
2.
20
)
1.
26
 (−
2.
17
 t
o 
4.
70
)
1.
14
 (−
1.
82
 t
o 
4.
10
)
 
 La
te
 r
em
is
si
on
 (A
U
D
IT
)
10
4
25
 (2
4.
0)
–
13
7
43
 (3
1.
4)
–
1.
31
 (0
.8
6 
to
 1
.9
9)
1.
44
 (0
.9
5 
to
 2
.2
0)
*P
<
0.
05
; *
*p
<
0.
01
; *
**
p
<
0.
00
1.
A
U
D
, a
lc
oh
ol
 u
se
 d
is
or
d
er
; A
U
D
IT
, A
lc
oh
ol
 U
se
 D
is
or
d
er
 Id
en
tifi
ca
tio
n 
Te
st
; B
L,
 B
as
el
in
e;
 P
H
Q
-9
, P
at
ie
nt
 H
ea
lth
 Q
ue
st
io
nn
ai
re
-9
 it
em
;R
R
, r
is
k 
ra
tio
; W
H
O
D
A
S
, W
H
O
 D
is
ab
ili
ty
 A
ss
es
sm
en
t 
S
ch
ed
ul
e.
 o
n
 4 June 2019 by guest. Protected by copyright.
http://gh.bmj.com/
BM
J G
lob Health: first published as 10.1136/bmjgh-2018-001344 on 19 May 2019. Downloaded from 
Shidhaye R, et al. BMJ Global Health 2019;4:e001344. doi:10.1136/bmjgh-2018-001344 11
BMJ Global Health
Response on the PHQ-9 at 3 months was significantly 
higher in the treatment group (52.2%) compared with the 
comparison group (26.9%) (adjusted risk ratio (aRR)=1.68; 
95% CI 1.22 to 2.30). The difference was still significant at 
12 months (aRR=1.56; 95% CI 1.16 to 2.10). The propor-
tion of participants reporting early remission (PHQ-9 <10 
at 3 months) on the PHQ-9 was greater among the treat-
ment participants (70.2%) compared with the comparison 
group (44.8%), (aRR=1.50; 95% CI 1.21 to 1.87). Recovery 
from depression (defined as PHQ-9 <10 at both 3 and 12 
months) was also significantly higher in the treatment 
group (56.1%) compared with the comparison group 
(28.5%) (aRR=1.82; 95% CI 1.33 to 2.48). There was no 
difference in late remission of depression in the treatment 
group compared with the comparison group. However, 
improvement in functioning was not different between the 
two groups at 3 months (β=−0.55; 95% CI −3.50 to 2.41) 
or 12 months (β=0.79; 95% CI −2.22 to 3.80). There was 
no evidence of non-equity in change in PHQ-9 scores at 12 
months across demographic groups (table 4).
Symptom severity decreased significantly over time 
among participants in the maternal depression cohort: 
the non-parametric paired tests showed a mean decrease 
in PHQ-9 scores of 7.50 points (95% CI −8.72 to −6.28; 
Z=−5.26, p<0.001), from baseline to 3 months, and a reduc-
tion of 8.4 points 95% CI −9.50 to −7.29; −5.02; p<0.001) 
from baseline to 12 months. The reduction in WHODAS 
scores was significant at 12 months (mean=−7.66; 95% CI 
−12.84 to −2.48; Z=−2.40; p=0.017), but not at 3 months 
(mean=−2.12; 95% CI −7.48 to 3.24; Z=−0.21, p=0.833). 
Also, 76.3% showed a response on the PHQ-9 at midline 
(95% CI 59.84% to 87.45%) and 78.8% (95% CI 61.06% 
to 89.80%) at endline. As in the depression cohort, there 
were no signs of inequity in reduction in PHQ-9 scores at 
12 months across demographic groups.
Alcohol use disorders
Characteristics of the participants
In the AUD cohort at baseline, 218 participants were 
recruited in the treatment group and 147 patients in the 
comparison group. Only one participant in the treatment 
group screened negative on the AUDIT and was excluded 
from the analysis; the final sample for the treatment group 
was 217. All but one of the participants recruited in the 
AUD cohort were males. The demographic and socio-eco-
nomic characteristics were otherwise similar for both 
groups (table 1). Baseline WHODAS and AUDIT scores 
did differ between the two groups, and so both scores were 
controlled for in subsequent analyses.
Follow-up rates at 3 months were 87.1% and 87.6% for 
the comparison and treatment groups, respectively, and 
80.3% and 80.2% at 12 months (figure 3).
Process data (AUD cohort participants)
Out of 217 participants enrolled in the AUD cohort, 
203 (93.6%) were delivered the first session of CAP. 
Only 12 participants (5.5%) completed four sessions 
of CAP. Treatment closure was done in 34 (15.7%) 
participants. Multi-vitamins were prescribed to 143 
(65.9%) participants. Thiamine was not prescribed as 
it was not available in CHCs.
Patient level outcomes
Change in symptom severity from baseline to 12 months 
was significantly different between the intervention and 
comparison groups in the AUD cohort (table 3): scores 
decreased by 6.0 points (95% CI −7.21, to 4.85) in the 
intervention group, compared with a reduction of 3.3 
points (95% CI −4.47 to 2.17) in the comparison group 
(β=−2.71; 95% CI −4.29 to −1.13). The improvement 
in functioning from baseline was not different between 
the two groups, whether at 3 months or 12 months after 
recruitment (table 3). The proportion of participants 
showing late remission, (AUDIT <8 at 12 months) was 
also not significantly different between the treatment 
group and the comparison group.
Table 5 presents the change in AUDIT scores from 
baseline to 12 months in the AUD cohort across demo-
graphic groups. Results of the Wald test suggest that 
the reduction in scores was greatest among those 
reporting no education and among those reporting 
more than primary education (Wald χ2=6.66; p=0.036), 
participants who had completed primary education 
(or above) had higher reduction in AUDIT scores. 
The reduction in AUDIT scores at 12 months was also 
marginally greater among younger participants (Wald 
χ2=3.94, p=0.083).
Psychosis
Characteristics of the participants
Finally, 22 participants were recruited in the psychosis 
cohort. Demographic information was available for 20 
of these participants, and the majority were between 30 
and 49 years of age (n=11, 55.0%), were male (n=13, 
65.0%), Hindu (n=18, 90.0%), married (n=14, 70.0%) 
and report achieving primary education or above (n=12, 
60.0%). Half of the participants were unemployed, and 
all but one reported being food secure (n=19, 95%). 
Eighteen participants (81.8%) were followed up at 3 
months and 12 months. We were unable to recruit the 
expected number of psychosis patients (N=150) in the 
cohort study as most of the patients with psychosis in 
the implementation area accessed care from psychia-
trists in Bhopal.
Process data (psychosis cohort participants)
Medications (anti-psychotics) were prescribed to 18 out 
of 22 (81.8%) participants and 20 participants (90.9%) 
were provided psychoeducation. Three follow-up 
sessions were completed by six participants (27.3 %).
Patient level outcomes
The non-parametric paired test suggests that the 
reduction in WHODAS scores among the participants 
recruited in the psychosis cohort was not significant, 
either at 3 months (β=−3.40; 95% CI −10.85 to 4.06; 
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Figure 3 Flow diagram of recruitment and follow-up process for the AUD cohort. AUD, alcohol use disorder; AUDIT, Alcohol 
Use Disorder Identification Test.
Z=−1.11; p=0.266) or 12 months (β=−6.25; 95% CI 
−14.74 to 2.24; Z=−1.63; p=0.103).
dISCuSSIon
We report the findings of the impact evaluation of 
PRIME, India, a multiplatform, multicomponent 
mental health programme, which aimed to integrate 
mental health services in primary care in Sehore district 
of Madhya Pradesh. PRIME MHCP did not have any 
impact on contact coverage for depression and AUD 
at the community level and a small impact on detec-
tion and initiation of treatment for depression and 
AUD in the health facilities. This seems to indicate that 
screening by PRIME Case Managers and training of 
medical officers had only a small impact on detection 
and treatment initiation. At the individual patient level, 
there was moderate impact of MHCP interventions. 
Patients with depression who received care as part of 
the MHCP had higher rates of response, early remis-
sion and recovery compared with those who did not 
receive care, but there was no impact of treatment on 
their functioning. It is difficult to attribute this impact 
to PRIME both due to the very low coverage of the 
evidence-based interventions as well as very large base-
line differences between the treatment and comparison 
cohorts. Thus, at district level, PRIME MHCP had no 
impact on improving the coverage of services at popu-
lation/community level, small impact on the health 
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systems/facility level outcomes and modest impact 
on patient/individual level outcomes. In the section 
below, we try to explain these findings.
Facility versus community focus
PRIME MHCP was designed to be implemented on the 
healthcare and community platforms and the emphasis 
was also to establish enabling packages to strengthen 
the health system. The Department of Health Services 
was primarily responsible for the delivery of mental 
health services while the role of the PRIME team was to 
be a facilitator and support team.6 Most of the govern-
ment health programme including the District Mental 
Health Program are healthcare platform centred as 
the priority of the government is to first establish the 
services in the ‘formal’ healthcare system using the 
infrastructure under their authority. Services are gener-
ally initiated in the District Hospital first, followed by 
Sub-District Hospitals/CHCs and then in primary 
healthcare centres (PHCs) (when the Government of 
Madhya Pradesh decided to scale up mental health 
services, ‘Mann-Kaksha’ were first established in the 
District Hospitals, this is described below). The unit of 
implementation in the original PRIME proposal was 
PHC, but in India it was changed to CHC based on 
inputs from the key stakeholders and to generally align 
PRIME work with the existing approach of the govern-
ment. As a result, facility processes on the healthcare 
platform took precedence over community processes 
and the Case Managers predominantly spent their time 
in CHCs to establish and optimise facility processes.
Retention in care
The biggest challenge in MHCP implementation was our 
inability to retain patients with depression and AUD in 
continuing care. Only 12.3% of patients with depression 
received four sessions of HAP while 5.5% of patients with 
AUD received four sessions of CAP. The treatment was 
generally acceptable to patients, but their willingness to 
come to the CHC for follow-up sessions was minimal. 
One possible option to improve retention in care was 
by providing home-based HAP/CAP sessions. Unfortu-
nately, provision of home-based therapy was not feasible 
in PRIME as Case Managers spent almost two-thirds of 
their time in the CHC. On other hand, we were unable 
to recruit additional human resources (eg, counsellors) 
through PRIME or the public health system to deliver 
home-based sessions of psychological interventions. In 
the PREMIUM trial which successfully demonstrated the 
effectiveness of HAP, 77% of the first sessions (typically 
on the day when patients were enrolled) were delivered 
in the PHC while 91% of the subsequent sessions were 
delivered at home.9 With hindsight, we feel that inability 
to plan home-based delivery of care was one of the major 
lacunae in programme design. Other possible options 
could have been involvement of CHWs such as ASHA in 
delivery of community interventions and follow-up care. 
Initially, efforts were made to involve ASHAs to screen 
patients in the community, provide MHFA, refer them 
to CHC and then provide follow-up care. ASHA workers 
receive monetary incentives mainly from the Maternal 
and Child Health programs to provide community-based 
care. We could not meaningfully engage ASHA workers 
for provision of psychological care as funds were not 
available either with PRIME or with the Government to 
give them incentives. This resulted in very low dosage 
of psychological intervention and should be considered 
as another major limitation of MHCP implementation. 
It must also be noted that around 1800 patients were 
enrolled in the programme while the cohort assessment 
only includes 400+ patients. In a trial, generally there are 
far more counsellors and number of patients per coun-
sellor is far less as compared with number of patients who 
were provided counselling by PRIME Case Managers. 
Another important consideration is that the trial is 
a time-bound process while PRIME implementation 
was designed as an ongoing activity and even after the 
cohort enrolment was stopped, new patients were getting 
enrolled in the programme and had to be followed up. 
The PRIME evaluation therefore represents an important 
real-world assessment of routine integration of mental 
healthcare into the primary care system. In addition to 
provision of HAP and CAP, Case Managers also had to 
spend time on activities related to enabling packages (eg, 
HMIS, drug procurement) and interventions on commu-
nity platform.
limited participation of the health system staff
PRIME Implementation at CHC level helped in reducing 
the ‘missed opportunity’21 to identify and treat patients 
attending outpatient clinics. The improvement in detec-
tion and initiation of treatment for depression and AUD 
was primarily due to screening by Case Managers and it 
was very modest, from 0% to 9.7% and 17.8%, respec-
tively. Under-detection and inability to treat depression 
and AUD in primary care is due to multiple factors which 
can be broadly classified into three categories; patient 
characteristics and preferences, provider knowledge and 
attitudes and health system related factors.22–25 Patients 
attending outpatient clinics were not primarily seeking 
care for mental health problems but for other physical 
ailments. Another important barrier is shorter consulta-
tion times in primary care. A recently published system-
atic review found that in 18 countries (which represent 
50% of the global population), patients spent less than 
5 min with their primary care physicians. In India the 
average consultation time was 2 min.26 In our setting as 
well, medical officers had very limited time for patient 
consultation, other CHC staff (eg, nurse) did not proac-
tively refer or detect patients ultimately resulting in only 
Case Managers dealing with screening and detection 
of depression and AUD. Due to time constraints, Case 
Managers could screen very limited numbers of patients 
attending outpatient clinics leading to minimal improve-
ments in this particular outcome.
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Community outreach
PRIME implementation did not lead to any change 
in access to mental healthcare at the community level. 
This can be primarily explained by limited delivery of 
community-based interventions by Case Managers. As the 
process data indicates, very few individuals in the commu-
nity were screened by Case Managers and were provided 
psychological first aid. Case Managers established link-
ages with CHWs such as Anganwadi workers and ASHA 
workers, but beyond facilitating visits of Case Managers 
the contribution of CHWs to screening and referral of 
individuals with depression, AUD and psychosis was 
minimal. One of the important reasons for this was lack 
of any incentive for CHWs to undertake these activities. 
VISHRAM (the Vidarbha Stress and Health Programme), 
a grass-roots community-based programme led by a team 
of CHWs and lay counsellors working in collaboration 
with primary care physicians and visiting psychiatrists led 
to a sixfold increase in contact coverage for depression.27 
This could be achieved due to a dedicated CHW in each 
of the 30 implementation villages as well as a range 
of community interventions undertaken by CHWs to 
improve mental health literacy. CHWs were paid an hono-
rarium of Rs. 1500 per month from the project funds. 
PRIME was implemented with far less human resource 
who had different set of responsibilities (primarily facility 
processes as explained above) and also had to cover a 
larger geographical area (PRIME community survey was 
done in 188 villages while VISHRAM survey and imple-
mentation was restricted to 30 villages). As mentioned 
earlier, in PRIME there was no provision to pay mone-
tary incentives to ASHA workers to undertake community 
level interventions.
limitations
There are several limitations to this study. The alloca-
tion of patients with depression/AUD to treatment/
comparison group was not random, which prevents 
us from drawing a causal inference about treatment–
outcome relationship. In addition to this, Case Managers 
proactively screened patients with depression/AUD and 
offered them treatment. They contacted those patients 
in OPD who were more likely to have depression/AUD. 
As a result, patients with higher mean PHQ-9/AUDIT 
scores were enrolled in treatment group. It is possible 
that higher change observed in mean scores in treat-
ment arms of both the cohorts is due to ‘regression to 
the mean’ phenomenon.28 We have not included corre-
lates of change in treatment outcomes in our analyses, 
including the role of retention and number of sessions 
received and this could be the focus of future research. 
Screening tools (PHQ-9 and AUDIT) were used to 
identify probable cases of depression and AUD which 
increases the risk of misclassification of these disorders. 
We used the Hindi versions of PHQ-9 and AUDIT used 
extensively in the PREMIUM trials.9 10 These tools were 
not further validated for the Hindi-speaking population 
of Sehore district, Madhya Pradesh. We were able to 
recruit only 22 patients in psychosis cohort, as most of 
them accessed care from psychiatrists in Bhopal. In FDS, 
outcome ascertainment was based on patient exit inter-
views only without simultaneous analysis of clinical notes. 
In CS, we were unable to contact 37.5% (baseline) and 
23.8% (follow-up) of the individuals sampled from the 
voter list which might have resulted in selection bias.
lessons learnt
Evaluation findings demonstrate minimal impact of 
PRIME MHCP on key primary outcomes, however, there 
are important lessons from the implementation of the 
MHCP which can be helpful in future integration of 
mental health services in primary care in low resource 
settings.
The key learnings are (1) mapping of service delivery 
processes on healthcare and community platform are 
helpful in monitoring/tracking the progress and iden-
tifying barriers in service delivery; (2) facilitation by an 
implementation support team can address some of these 
barriers; (3) enabling packages of MHCP play a crucial 
role in strengthening the health system and improving 
the context and settings for implementation; (4) engage-
ment with key community stakeholders and incentives for 
CHWs (ASHAs in case of India) are necessary to deliver 
services on the community platform.
Sustainability and implications for mental health practice
In 2015, Department of Health Services decided to scale up 
the PRIME model across 51 District Hospitals in Madhya 
Pradesh.29 As part of this initiative, ‘Mann-Kaksha’ were 
established in District Hospitals and a minimum of two 
nurses and one medical officer from each district were 
trained to provide mental health services. The sugges-
tion to appoint Case Managers in District Hospitals was 
not accepted, but it was decided that nurses will fulfil the 
functions of Case Managers. Very recently, operational-
isation of ‘Mann-Kaksha’ to strengthen mental health 
services was awarded as a best practice by the National 
Health Mission.30 The adoption of the PRIME Implemen-
tation model by the Government of Madhya Pradesh for 
state-wide scale up of mental health services ensures the 
sustainability of the work initiated by PRIME.
ConCluSIonS
Establishing a collaborative model of care remains a very 
challenging task, especially in resource poor settings. 
Facilitation by an implementation support team can 
play an important role in establishing enabling pack-
ages related to governance, health information systems 
and so on which serve as foundation to instal, optimise 
and improve service delivery processes. Training of 
primary care physicians alone is not a sufficient inter-
vention to improve diagnosis and provision of mini-
mally adequate treatment for priority mental disorders. 
Routine screening of these disorders and inclusion of 
quality improvement strategies to improve various care 
processes must be included in future implementation of 
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mental health programme. Our major learning is that 
psychosocial therapies cannot be effectively delivered 
without engaging existing or new community resources. 
While dedicated human resources (eg, Case Managers) 
and dedicated space for mental health clinics (eg, Mann-
Kaksha) strengthen the facility/healthcare platform, 
CHWs such as ASHAs could be potentially trained to 
deliver psychosocial interventions in the community 
ensuring delivery of the adequate dosage of the interven-
tion. A crucial lesson is that without substantial additional 
investments in staff, such as CHWs/ASHAs to improve 
community level case detection and conduct home visits 
to deliver the HAP and CAP psychological treatments, we 
are unlikely to see major changes in coverage or clinical 
outcomes. One of the key actions recommended by the 
recently launched Lancet Commission on global mental 
health and sustainable development31 is substantial addi-
tional investment in mental health and redistribution of 
mental health budgets from large hospitals to District 
Hospital and community- based local services. Strong 
advocacy efforts are needed at national and provincial 
level to implement these recommendations by allocating 
resources to recruit and train community health workers 
to deliver mental healthcare in the community. It is also 
important to recognise that mental health programme 
must be both bottom up and top-down (ie, community 
driven and healthcare facility driven, and addressing 
both supply-side and demand-side factors). In addition to 
the primary healthcare system, local communities should 
be involved in mental health programme as it was done 
in the VISHRAM programme.27 A synthesis of learn-
ings from PRIME and VISHRAM model can potentially 
inform scaling up of mental health services across India 
through the National Mental Health Programme.
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